A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity
Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype
Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease
Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
- « Previous Page
- 1
- …
- 10
- 11
- 12